Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.

Nature - 1 May 2021

Wang Pengfei, Nair Manoj S, Liu Lihong, Iketani Sho, Luo Yang, Guo Yicheng, Wang Maple, Yu Jian, Zhang Baoshan, Kwong Peter D, Graham Barney S, Mascola John R, Chang Jennifer Y, Yin Michael T, Sobieszczyk Magdalena, Kyratsous Christos A, Shapiro Lawrence, Sheng Zizhang, Huang Yaoxing, Ho David D

Abstract excerpt

The COVID-19 pandemic has had widespread effects across the globe, and its causative agent, SARS-CoV-2, continues to spread. Effective interventions need to be developed to end this pandemic. Single and combination therapies with monoclonal antibodies have received emergency use authorization1-3, and more treatments are under development4-7. Furthermore, multiple vaccine constructs have shown promise8, including...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Neutralizing
Share to COVID-19 Drug Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to COVID-19 Vaccines

Share to Immune Evasion

Share to Immunization, Passive

Share to Neutralization Tests

Share to Vaccines, Synthetic

Share to Vero Cells

Source

Identifiers

PMID: 33684923
DOI: 10.1038/s41586-021-03398-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.PMID 33684923Read ↗

Serum Neutralizing Activity against B.1.1.7, B.1.351, and P.1 SARS-CoV-2 Variants of Concern in Hospitalized COVID-19 Patients.Semantic proximity Read ↗

SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodiesSemantic proximity Read ↗

Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines.Semantic proximity Read ↗

Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individualsSemantic proximity Read ↗

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies.Semantic proximity Read ↗

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodiesSemantic proximity Read ↗

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodiesSemantic proximity Read ↗

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines.Semantic proximity Read ↗

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.Semantic proximity Read ↗

Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2.Semantic proximity Read ↗

SARS-CoV-2 variants resist antibody neutralization and broaden host ACE2 usageSemantic proximity Read ↗

In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strainsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.